The Diabetes and Liver Disease (DLD) Sub Committee was formed in 2022 under the guidance of the ADS Clinical/Standards Advisory Committee (CAC).
Chair: Prof Stephen Twigg
Members: Prof Jonathan Shaw, Dr Mark Gorrell, Dr Sarah Parry, Sunita Date, Prof Tania Markovic, Prof Tim Davis, Dr Thora Chai, Ms Natalie Wischer, A/Prof Ashim Sinha, Prof Jacob George, Dr Leons Adams, Dr Koya Ayonrinde
(a) The Australian Diabetes Society (Society) Diabetes and Liver Disease (DLDS or subcommittee) is a subcommittee to the Clinical
Guidelines/Standards Advisory Committee (CAC) that provides advice to the Society’s Council (Council).
(b) The DLDS aims to promote and support high quality clinical guidelines and standards for the prevention, diagnosis and management of diabetes mellitus as it pertains specifically to liver disease.
(a) The Subcommittee’s functions are:
(i) To provide advice to the CAC on clinical guidelines/standards priorities;
(ii) To identify, oversee and prioritise new position statements, with relevant guidelines and treatment/management algorithms for the Society addressing diabetes and liver disease (DLD);
(iii) To review and provide input and guidance into relevant NADC and DFA standards to the CAC;
(iv) To respond to requests to review and provide input/comments into standards, guidelines and position statements developed by other external groups specifically in DLD as requested by the CAC, including DA, ADEA, ADIPS, APEG, RACP, RACGP, CSANZ, ANZSN;
(v) Such other functions as are reasonably determined by the CAC.
(b) Office bearers and members of the DLDS must obtain express written permission from the Chair of the CAC, and also from the Council or President of the Council, before purporting to act or communicate on behalf of the Society or the Council.